Background: SGI-110 is a dinucleo- SGI-110 tide of decitabine (DAC) and deoxyguanosine formulated as a small volume SQ injection that extends DAC exposure compared to DAC IV. Our in vitro and in vivo evidence identified a strong immunomodulatory activity of SGI-110 on human cancer cells of different histotype and on human melanoma xenografts. We also showed a remarkable anti-tumor effect once combined with anti-CTLA-4 mAb in a syngeneic mouse model. In this study we evaluated the contribution of antitumor immune responses in the reduction of tumor growth achieved by this therapeutic combination.
View further details below
2014 EORTC: Epigenetic immunomodulation by SGI-110 combined with immune check-point blockade